Literature DB >> 11264983

Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis.

L L Rudel1, R G Lee, T L Cockman.   

Abstract

Two enzymes are responsible for cholesterol ester formation in tissues, acyl coenzyme A:cholesterol acyltransferase types 1 and 2 (ACAT1 and ACAT2). The available evidence suggests different cell locations, membrane orientations, and metabolic functions for each enzyme. ACAT1 and ACAT2 gene disruption experiments in mice have shown complementary results, with ACAT1 being responsible for cholesterol homeostasis in the brain, skin, adrenal, and macrophages. ACAT1 -/- mice have less atherosclerosis than their ACAT1 +/+ counterparts, presumably because of the decreased ACAT activity in the macrophages. By contrast, ACAT2 -/- mice have limited cholesterol absorption in the intestine, and decreased cholesterol ester content in the liver and plasma lipoproteins. Almost no cholesterol esterification was found when liver and intestinal microsomes from ACAT2 -/- mice were assayed. Studies in non-human primates have shown the presence of ACAT1 primarily in the Kupffer cells of the liver, in non-mucosal cell types in the intestine, and in kidney and adrenal cortical cells, whereas ACAT2 is present only in hepatocytes and in intestinal mucosal cells. The membrane topology for ACAT1 and ACAT2 is also apparently different, with ACAT1 having a serine essential for activity on the cytoplasmic side of the endoplasmic reticulum membrane, whereas the analogous serine is present on the lumenal side of the endoplasmic reticulum for ACAT2. Taken together, the data suggest that cholesterol ester formation by ACAT1 supports separate functions compared with cholesterol esterification by ACAT2. The latter enzyme appears to be responsible for cholesterol ester formation and secretion in lipoproteins, whereas ACAT1 appears to function to maintain appropriate cholesterol availability in cell membranes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264983     DOI: 10.1097/00041433-200104000-00005

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  60 in total

Review 1.  Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling.

Authors:  Rosalind A Coleman; Douglas G Mashek
Journal:  Chem Rev       Date:  2011-06-01       Impact factor: 60.622

2.  Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine.

Authors:  Chang Xie 谢畅; Zhang-Sen Zhou 周章森; Na Li 李钠; Yan Bian 卞艳; Yong-Jian Wang 王永建; Li-Juan Wang 王丽娟; Bo-Liang Li 李伯良; Bao-Liang Song 宋保亮
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

Review 3.  Role of the gut in lipid homeostasis.

Authors:  Nada A Abumrad; Nicholas O Davidson
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

4.  Investigating the allosterism of acyl-CoA:cholesterol acyltransferase (ACAT) by using various sterols: in vitro and intact cell studies.

Authors:  Jay Liu; Catherine C Y Chang; Emily J Westover; Douglas F Covey; Ta-Yuan Chang
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

5.  Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels.

Authors:  Tinghuai Wu; Masashi Fujihara; Jane Tian; Miroslava Jovanovic; Celene Grayson; Marisol Cano; Peter Gehlbach; Philippe Margaron; James T Handa
Journal:  J Neurochem       Date:  2010-07-27       Impact factor: 5.372

Review 6.  Intestinal nuclear receptors in HDL cholesterol metabolism.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  J Lipid Res       Date:  2014-07-28       Impact factor: 5.922

7.  Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Emily L Willner; Bryan Tow; Kimberly K Buhman; Martha Wilson; David A Sanan; Lawrence L Rudel; Robert V Farese
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 8.  Newer pharmaceutical agents to treat lipid disorders.

Authors:  Michael H Davidson
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

9.  Identification of the interaction site within acyl-CoA:cholesterol acyltransferase 2 for the isoform-specific inhibitor pyripyropene A.

Authors:  Akash Das; Matthew A Davis; Hiroshi Tomoda; Satoshi Omura; Lawrence L Rudel
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

10.  Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.

Authors:  Paolo Parini; Ulf Gustafsson; Matt A Davis; Lilian Larsson; Curt Einarsson; Martha Wilson; Mats Rudling; Hiroshi Tomoda; Satoshi Omura; Staffan Sahlin; Bo Angelin; Lawrence L Rudel; Mats Eriksson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-13       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.